AUS
NZ
UK
CA
USA
IND
_06_16_2026_04_54_27_535266.jpg)
Highlights
- Equity research from Jefferies Financial Group and others have adjusted price targets and ratings for Corbus Pharmaceuticals (NASDAQ:CRBP) amid fluctuating market conditions.
- Institutional investors are actively trading shares, with a notable percentage of the company owned by these entities.
- Corbus Pharmaceuticals continues to advance its pipeline products, targeting innovative treatments for serious illnesses such as cancer and obesity.
Corbus Pharmaceuticals (NASDAQ:CRBP) has attracted significant attention from equity researchers, leading to updated price objectives and varied stock ratings. Recently, Jefferies Financial Group adjusted its price objective from $70.00 to $53.00 while maintaining a "buy" rating. Other analysts have expressed differing opinions, with some assigning an "outperform" rating and others opting for a "sell" rating. Despite these differences, a consensus target price of $59.13 arises based on data from MarketBeat.com, suggesting a generally positive outlook among analysts.
Stock Performance and Financial Indicators
The company's stock opened at $6.91, and its performance over the past year highlights a high degree of volatility. The 50-day simple moving average is $9.67, whereas the 200-day average stands at $19.44. With a market capitalization of $84.16 million, the biopharmaceutical company exhibits a beta of 2.63, indicating potentially high risk and volatility relative to the market. Financially, Corbus Pharmaceuticals posted earnings indicating a beat against analysts’ expectations, with a reported EPS of ($0.78) compared to the anticipated ($1.02).
Institutional Investment Activity
Institutional investors have been active in trading shares of Corbus Pharmaceuticals. JPMorgan Chase & Co., the Manufacturers Life Insurance Company, and Wells Fargo & Company MN have all adjusted their holdings in the company, reflecting varying strategies. In the third quarter, JPMorgan increased its position by 27%, while the Manufacturers Life Insurance Company upped its holdings by 7.6%. Such movements highlight the dynamic nature of institutional investment strategies and further emphasize the strong institutional ownership of Corbus Pharmaceuticals, which stands at 64.64%.
Research and Development Pipeline
At the core of Corbus Pharmaceuticals' operations is its dedication to developing novel treatments for serious conditions. The company's pipeline includes CRB-701, an antibody-drug conjugate currently in Phase I clinical trials targeting cancer cells. Meanwhile, CRB-601 aims to block cancer cell activation for the treatment of solid tumors, and CRB-913 focuses on obesity treatment. These innovative efforts underscore the company's commitment to advancing medical science and addressing unfulfilled medical needs.
